Drug combination for peripheral T-cell lymphoma patients unable to take intensive chemo
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This trial tests a combination of three drugs — golidocitinib, azacitidine, and chidamide — for people with peripheral T-cell lymphoma who cannot receive standard intensive chemotherapy. The goal is to see if this combination can help control the lymphoma with fewer side effects.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have a confirmed diagnosis of peripheral T-cell lymphoma.
- You should be able to care for yourself (fully or with some help) — your doctor will check this.
- You should have at least one tumor that can be measured on scans or exams.
- You should not be a good candidate for standard intensive chemotherapy — this trial is for people who can't tolerate it, often because of age or other health issues.
- You must agree to use effective birth control during treatment and for 6 months after the last dose (if applicable).
- You should not have untreated or serious heart, blood, or other major health problems that would make the trial unsafe.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of two drugs, chidamide and golidocitinib, for peripheral T-cell lymphoma that has come back or not responded to earlier treatments. The goal is to see if this combination can help shrink or control the lymphoma.
This trial tests a combination of a targeted drug (golidocitinib) with either a chemotherapy liposome or another targeted drug (chidamide) for people with peripheral T-cell lymphoma that has come back or stopped responding to treatment. The goal is to see if the combination works better than current options.
This trial tests a new drug, golidocitinib, against a standard treatment chosen by your doctor for peripheral T-cell lymphoma that has come back or not responded to prior therapy. The goal is to see which approach works better for patients.
This study tests a combination of three drugs (azacitidine, chidamide, and a PD-1 inhibitor) for T-cell lymphomas that have returned or stopped responding to previous treatment. The goal is to see if this combination can help shrink the cancer.
This trial tests a combination treatment for peripheral T-cell lymphoma, a type of blood cancer. It may help patients who cannot tolerate standard chemotherapy or whose disease has come back.
This trial tests two medications (golidocitinib and chidamide) for people with a type of lymphoma that affects the skin. The combo may help control the disease when other treatments haven't worked or have stopped working.
Hear when a new Peripheral T-Cell Lymphoma, Not Classified trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.